Kairos Pharma (KAPA) shares were down 14% in recent Tuesday trading after the company said it received approval to dual list its stock on Upstream, a global trading app for digital securities.
With the dual listing, the company said it can access a global investor base outside the US for additional liquidity and price discovery enhancement.
The Upstream platform facilitates real-time trading and settlement, and ensures a transparent orderbook that does not allow common market manipulations, Kairos said.
Price: 1.43, Change: -0.28, Percent Change: -16.37